Aug 13 |
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
|
Aug 12 |
Medical journal retracts three articles related to MDMA for PTSD
|
Aug 12 |
Mind Medicine Q2 2024 Earnings Preview
|
Aug 9 |
Psychedelic drug developers face setback as ecstasy-based drug rejected by FDA
|
Aug 9 |
Mind Medicine prices $75M securities offering
|
Aug 9 |
Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering
|
Aug 9 |
Mind Medicine stock dips on proposed securities offering
|
Aug 9 |
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
|
Aug 7 |
MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy
|
Aug 6 |
MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference
|